Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
09.04. | ENZYMATICA AB: Enzymatica publishes annual report for 2023 | 1 | Cision News | ||
27.03. | Notice of Annual General Meeting 2024 in Enzymatica AB (publ) | 220 | PR Newswire | The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text shall prevail.
LUND, Sweden , March... ► Artikel lesen | |
27.03. | Nasdaq Stockholm AB: Last day of trading in paid subscription shares (BTA) of Enzymatica AB | 160 | GlobeNewswire | Trading in Enzymatica AB paid subscription shares is to cease. The last trading
day is April 2, 2024.
Short name: ENZY BTA
ISIN code: SE0021626710
Orderbook ID: 325501
This information is distributed... ► Artikel lesen | |
15.03. | Enzymatica AB: Enzymatica announces outcome of new rights issue | 367 | PR Newswire | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, SINGAPORE
THE... ► Artikel lesen | |
11.03. | Enzymatica AB: ColdZyme® certified under the new EU medical device regulation (MDR) | 468 | PR Newswire | LUND, Sweden, March 11, 2024 /PRNewswire/ -- Enzymatica's mouth spray ColdZyme® has received CE-certification under the new and more demanding European Union medical device regulation (MDR).... ► Artikel lesen | |
27.02. | Nasdaq Stockholm AB: Listing of subscription rights and paid subscription shares of Enzymatica AB (97/24) | 285 | GlobeNewswire | With effect from February 28, 2024, the subscription rights in Enzymatica AB
will be traded on First North Growth Market. Trading will continue up until and
including March 08, 2024.
Instrument:... ► Artikel lesen | |
26.02. | ENZYMATICA AB: Enzymatica's partners await MDR certification and study results | 1 | Cision News | ||
22.02. | XFRA CAPITAL ADJUSTMENT INFORMATION - 22.02.2024 | 421 | Xetra Newsboard | Das Instrument EN9 SE0003943620 ENZYMATICA AB EQUITY wird ex Kapitalmassnahme gehandelt am 22.02.2024 The instrument EN9 SE0003943620 ENZYMATICA AB EQUITY is traded ex capital adjustment on 22.02.2024Das... ► Artikel lesen | |
19.02. | Enzymatica AB: Enzymatica publishes information memorandum about rights issue of shares | 581 | PR Newswire | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, RUSSIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND,... ► Artikel lesen | |
16.02. | Enzymatica AB: Enzymatica's rights issue is secured to 100 percent | 284 | PR Newswire | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, SINGAPORE
THE... ► Artikel lesen | |
16.02. | Enzymatica AB: Year-end report 2023: Scientific and regulatory progress generating international interest | 185 | PR Newswire | LUND, Sweden, Feb. 16, 2024 /PRNewswire/ --
Fourth quarter
January-December
• Net sales reached SEK 15.8 (16.6) million.
• The operating result totaled SEK... ► Artikel lesen | |
16.02. | Enzymatica AB: Enzymatica's Board of Directors decides on a new rights issue of SEK 27.4 million | 308 | PR Newswire | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, HONGKONG, JAPAN, CANADA, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, SINGAPORE
THE... ► Artikel lesen | |
30.11.23 | ENZYMATICA AB: Enzymatica changes Certified Adviser to Carnegie Investment Bank AB (publ) | 3 | Cision News | ||
08.11.23 | ENZYMATICA AB: Enzymatica focuses on strengthening the distributor level | 4 | Cision News | ||
07.11.23 | Enzymatica AB - Interim report Q3/2023: Research results that reshape the competitive landscape | 350 | PR Newswire | LUND, Sweden, Nov. 7, 2023 /PRNewswire/ --
Third quarter
January-September
Net sales reached SEK 13.3 (18.5) million.
The operating result totaled SEK -8.7 (-12.6) million.
Earnings... ► Artikel lesen | |
21.09.23 | Enzymatica AB: Interim report from clinical study: ColdZyme significantly reduces rhinovirus viral load and symptoms of sore throat | 304 | PR Newswire | LUND, Sweden, Sept. 21, 2023 /PRNewswire/ -- The first results from an ongoing independent clinical study at the University of Kent, UK, show that ColdZyme® significantly reduces the viral... ► Artikel lesen | |
22.08.23 | New study: ColdZyme breaks viral infection cycle - significantly reducing influenza viral load - Enzymatica AB | 414 | PR Newswire | LUND, Sweden, Aug. 22, 2023 /PRNewswire/ -- ColdZyme® reduces viral load by more than 99 percent when applied onto human cells that have been infected with influenza A (H3N2), compared to... ► Artikel lesen | |
18.07.23 | Enzymatica AB: Enzymatica Interim report Q2/2023: An exciting and important time ahead | 357 | PR Newswire | LUND, Sweden, July 18, 2023 /PRNewswire/ --
Q2
H1
Net sales reached SEK 8.8 (9.6) million.
The operating result totaled SEK... ► Artikel lesen | |
04.05.23 | Bulletin from Annual General Meeting of Enzymatica AB (publ) | 361 | PR Newswire | LUND, Sweden, May 4, 2023 /PRNewswire/ -- The English text is an unofficial translation. In case of any discrepancies between the Swedish text and the English translation, the Swedish text... ► Artikel lesen | |
27.04.23 | Enzymatica AB: Interim report Q1/2023: Strong start to the year - Enzymatica's growth journey continues according to plan | 421 | PR Newswire | LUND, Sweden, April 27, 2023 /PRNewswire/ --
First quarter
Net sales reached SEK 13.0 (4.2) million.The operating result totaled SEK -14.4 (-18.1) million.Earnings per share... ► Artikel lesen |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BAYER | 26,120 | -0,46 % | KI im Gesundheitswesen mit evotec, Defence Therapeutics, Bayer: Revolutionäre Fortschritte und medizinische Durchbrüche | Im Gesundheitswesen nimmt Künstliche Intelligenz (KI) immer mehr an Fahrt auf. KI-basierte Systeme können medizinische Datenbanken nutzen, um in der Forschung kostbare Zeit zu sparen, die es Unternehmen... ► Artikel lesen | |
PFIZER | 23,795 | -0,23 % | JPMORGAN stuft PFIZER INC auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat die Einstufung für Pfizer vor Zahlen fürs erste Quartal auf "Neutral" mit einem Kursziel von 30 US-Dollar belassen. Der Pharmakonzern dürften die... ► Artikel lesen | |
NOVO NORDISK | 115,68 | -0,17 % | Bullisches Signal für Biotech-Aktie: Löst das eines der größten Probleme von Novo Nordisk? | Eine neue strategische Partnerschaft könnte der Aktie von Novo Nordisk demnächst weitere Kurssprünge einbringen, da sie ein akutes Problem des Biotechriesen lösen könnte. Das sollten Anleger wissen.... ► Artikel lesen | |
GILEAD SCIENCES | 61,71 | -0,72 % | Virushepatitis bis 2030 eliminieren: Gilead Sciences fördert zahlreiche Projekte weltweit mit 4 Millionen US-Dollar - auch in Deutschland | Martinsried bei München (ots) - - Gilead vergibt 4 Millionen US-Dollar weltweit (ohne die Vereinigten Staaten) durch das Förderprogramm "ALL4LIVER Grant" -- Die World Hepatitis Alliance und hochrangige... ► Artikel lesen | |
SANOFI | 85,42 | -0,09 % | Minimale Kursveränderung bei Aktie von Sanofi SA (86,55 €) | Am Aktienmarkt ist das Wertpapier von Sanofi SA aktuell unauffällig. Zuletzt zahlten Investoren für das Wertpapier 86,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Sanofi... ► Artikel lesen | |
GSK | 18,490 | +0,35 % | GSK Says ZOSTER-049 Study Showed Its Shingles Vaccine Maintains Long-term Efficacy | LONDON (dpa-AFX) - GSK plc (GSK.L) Wednesday announced positive data from the ZOSTER-049 long-term follow-up phase III trial of its shingles vaccine, Shingrix.Final data from ZOSTER-049 study... ► Artikel lesen | |
STADA ARZNEIMITTEL | - | - | IPO/Kreise: Stada-Eigner bereden erneuten Börsengang und Verkaufsoptionen | BAD VILBEL (dpa-AFX) - Der Pharmakonzern Stada könnte Insidern zufolge an die Börse zurückkehren. Die Eigentümer des Bad Vilbeler Unternehmens, die Finanzinvestoren Bain Capital und Cinven, erörterten... ► Artikel lesen | |
ABBVIE | 153,36 | -0,88 % | Dividendenbekanntmachungen (12.04.2024) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABBOTT LABORATORIES US0028241000 0,55 USD 0,5127 EUR ABBVIE INC US00287Y1091 1,55 USD 1,4449 EUR ABBVIE INC CDR CA00288K1084 0... ► Artikel lesen | |
CANOPY GROWTH | 7,020 | -4,75 % | Aurora Cannabis & Canopy Growth: Deshalb ziehen sie an | Die Aurora Cannabis-Aktie (WKN: A2P4EC) und die Aktie von Canopy Growth (WKN: A140WQA) haben am Donnerstag plötzlich einen massiven Kurssprung von über +20% vollführt. Das steckt hinter dem rasanten... ► Artikel lesen | |
ASTRAZENECA | 127,95 | -0,31 % | BARCLAYS stuft ASTRAZENECA auf 'Overweight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Astrazeneca vor Quartalszahlen und dem Investorentag des Pharmakonzerns von 12500 auf 13000 Pence angehoben und... ► Artikel lesen | |
INNOCAN PHARMA | 0,180 | -2,44 % | X-Leak: Jetzt der Mega-Meilenstein - Kurseskalation vorprogrammiert? | ||
VERTEX PHARMACEUTICALS | 368,70 | -0,26 % | Vertex Pharmaceuticals Incorporated: Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain | Rolling submission for suzetrigine moderate-to-severe acute pain NDA granted by FDA; first module submitted and on track to complete filing this quarter -
Successful completion of end-of-phase 2... ► Artikel lesen | |
TAAT GLOBAL ALTERNATIVES | 0,159 | -9,69 % | TAAT Global Alternatives Inc (2): TAAT to issue update on FY 2023 results filing April 26 | ||
CRONOS GROUP | 2,226 | -1,50 % | Cronos Group Inc. - 8-K, Current Report | ||
VIATRIS | 10,440 | -0,05 % | Viatris Inc.: Viatris Appoints Corinne Le Goff as Chief Commercial Officer | PITTSBURGH, April 15, 2024 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that Corinne Le Goff has joined the company as Chief Commercial Officer and... ► Artikel lesen |